- Retinal dystrophy treatment focuses on managing a group of inherited retinal disorders that cause progressive vision loss due to photoreceptor degeneration. These include conditions such as retinitis pigmentosa and Leber congenital amaurosis
- The market growth is significantly driven by advancements in gene therapy, increasing R&D funding, and growing awareness of early genetic screening and diagnosis
- North America is expected to dominate the retinal dystrophy treatments market, with a share of 40.5%, due to a high number of clinical trials, advanced healthcare facilities, and the presence of major biotechnology companies
- Asia-Pacific is expected to be the fastest growing region in the Retinal Dystrophy Treatment market during the forecast period due to rising healthcare investments, expanding access to ophthalmic care, and increasing government initiatives to support rare disease treatment
- Gene therapy segment is expected to dominate the market with a market share of 45.5% due to its ability to address the root cause of inherited retinal dystrophies by correcting defective genes. This approach offers long-term and potentially curative outcomes, unlike traditional symptomatic treatments. Growing approvals, such as Luxturna, and robust clinical pipelines further drive its adoption and market leadership
